762 related articles for article (PubMed ID: 27620276)
1. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
2. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ; Stannard K; Liu J; Allen S; Yong MC; Mittal D; Aguilera AR; Miles JJ; Lutzky VP; de Andrade LF; Martinet L; Colonna M; Takeda K; Kühnel F; Gurlevik E; Bernhardt G; Teng MW; Smyth MJ
Cancer Discov; 2016 Apr; 6(4):446-59. PubMed ID: 26787820
[TBL] [Abstract][Full Text] [Related]
4. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
5. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
6. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
Jin HS; Park Y
BMB Rep; 2021 Jan; 54(1):2-11. PubMed ID: 33298247
[TBL] [Abstract][Full Text] [Related]
7. Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.
Farhangnia P; Akbarpour M; Yazdanifar M; Aref AR; Delbandi AA; Rezaei N
Expert Rev Clin Immunol; 2022 Dec; 18(12):1217-1237. PubMed ID: 36154551
[TBL] [Abstract][Full Text] [Related]
8. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
[TBL] [Abstract][Full Text] [Related]
9. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
[TBL] [Abstract][Full Text] [Related]
11. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
Gorvel L; Olive D
F1000Res; 2020; 9():. PubMed ID: 32489646
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the Characteristics of TIGIT-Expressing CD3
Zhang X; Lu X; Cheung AKL; Zhang Q; Liu Z; Li Z; Yuan L; Wang R; Liu Y; Tang B; Xia H; Wu H; Zhang T; Su B
Front Immunol; 2021; 12():602492. PubMed ID: 33717085
[TBL] [Abstract][Full Text] [Related]
13. Coming of Age: CD96 Emerges as Modulator of Immune Responses.
Georgiev H; Ravens I; Papadogianni G; Bernhardt G
Front Immunol; 2018; 9():1072. PubMed ID: 29868026
[TBL] [Abstract][Full Text] [Related]
14. TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy.
Liu XG; Hou M; Liu Y
Immunol Invest; 2017 Feb; 46(2):172-182. PubMed ID: 27819527
[TBL] [Abstract][Full Text] [Related]
15. CD96 Is an Immune Checkpoint That Regulates CD8
Mittal D; Lepletier A; Madore J; Aguilera AR; Stannard K; Blake SJ; Whitehall VLJ; Liu C; Bettington ML; Takeda K; Long GV; Scolyer RA; Lan R; Siemers N; Korman A; Teng MWL; Johnston RJ; Dougall WC; Smyth MJ
Cancer Immunol Res; 2019 Apr; 7(4):559-571. PubMed ID: 30894377
[TBL] [Abstract][Full Text] [Related]
16. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
[TBL] [Abstract][Full Text] [Related]
17. [CD226, TIGIT and CD96 regulate NK cell function and participate in anti-tumor immunity].
Zhang H; Liu R; Zhang Y; Liu X; Chen L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):852-856. PubMed ID: 37732582
[TBL] [Abstract][Full Text] [Related]
18. Fcγ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies.
Rogel A; Ibrahim FM; Thirdborough SM; Renart-Depontieu F; Birts CN; Buchan SL; Preville X; King EV; Al-Shamkhani A
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 35998045
[TBL] [Abstract][Full Text] [Related]
19. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]